Top Markets
#1 DogBull DogBull +106.78%
#2 Siacoin Siacoin +54.82%
#3 ADO Protocol ADO Protocol +51.26%
#4 The Bitcoin Bull The Bitcoin Bull +43.78%
#5 MarsCoin MarsCoin +38.18%
#6 Glidr Glidr +27.02%
#7 龙虾 (Lobster) 龙虾 (Lobster) +24.13%
#8 Ontology Gas Ontology Gas +21.77%
#9 UnifAI Network UnifAI Network +19.84%
#10 Falcon Finance Falcon Finance +17.95%
Coin of the day
DogBull DogBull
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Kedudukan dalam Saham #15657
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Harga Saham
$0.63963115
Disegerakkan terakhir: 2026-08-26
Modal Pasaran
$339.16M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-35.23%
Negara
CN
Perdagangan Jiangsu Recbio Technology Co., Ltd. (2179)

Kategori

Healthcare
Margin Operasi untuk Jiangsu Recbio Technology Co., Ltd. (2179)
Margin Operasi pada 2026 TTM: 0.00%
Menurut laporan kewangan dan harga saham terkini Jiangsu Recbio Technology Co., Ltd., margin operasi semasa (TTM) ialah 0.00%. Pada akhir 2026, margin operasi syarikat ialah 0.00%.
Sejarah Margin Operasi untuk Jiangsu Recbio Technology Co., Ltd. dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Ubah
Tidak cukup data untuk tarikh yang disediakan.
Margin Operasi untuk syarikat serupa atau pesaing
Syarikat Margin Operasi Perbezaan Margin Operasi Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.